CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Consensus Rating of “Moderate Buy” from Brokerages

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has earned an average recommendation of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $8.3571.

A number of analysts recently commented on the company. Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 10th. Rodman & Renshaw assumed coverage on CAMP4 Therapeutics in a research report on Tuesday, April 14th. They set a “buy” rating and a $7.00 price objective for the company. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Cantor Fitzgerald reiterated an “overweight” rating on shares of CAMP4 Therapeutics in a research report on Friday, March 6th. Finally, Leerink Partners lifted their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, April 2nd.

Institutional Trading of CAMP4 Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. purchased a new stake in CAMP4 Therapeutics during the 4th quarter worth about $61,000. Jefferies Financial Group Inc. purchased a new stake in CAMP4 Therapeutics during the 4th quarter worth about $70,000. Bank of America Corp DE purchased a new stake in CAMP4 Therapeutics during the 4th quarter worth about $86,000. OMERS ADMINISTRATION Corp purchased a new stake in CAMP4 Therapeutics during the 4th quarter worth about $115,000. Finally, Goldman Sachs Group Inc. purchased a new stake in CAMP4 Therapeutics during the 4th quarter worth about $115,000.

CAMP4 Therapeutics Stock Performance

CAMP4 Therapeutics stock opened at $4.20 on Monday. The firm has a market capitalization of $218.11 million, a price-to-earnings ratio of -1.78 and a beta of 0.08. CAMP4 Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $7.75. The stock’s fifty day moving average is $4.28 and its two-hundred day moving average is $4.74.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The firm had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. As a group, sell-side analysts forecast that CAMP4 Therapeutics will post -0.84 EPS for the current fiscal year.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.